US2006073157A1PendingUtilityA1

Attenuated live Neospora vaccine

52
Individually held — no corporate assignee on recordPriority: Nov 12, 1996Filed: Oct 27, 2005Published: Apr 6, 2006
Est. expiryNov 12, 2016(expired)· nominal 20-yr term from priority
Inventors:David BrakeByron L. BlagburnDavid Lindsay
C07K 14/44A61K 2039/552A61K 39/002A61P 33/02A61P 33/00A61K 2039/522
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides attenuated live cultures of the pathogenic protozoan parasite, Neospora, and live vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals.

Claims

exact text as granted — not AI-modified
1 . A culture of cells of a strain derived from a pathogenic parent strain of a species of  Neospora,  which cells exhibit attenuated pathogenicity compared to those of the parent strain but which are capable of triggering an immune response that protects a mammal against neosporosis when administered as a live vaccine.  
   
   
       2 . (canceled)  
   
   
       3 . The culture of  claim 1 , wherein the species of the parent strain is  N. caninum.    
   
   
       4 . The culture of  claim 3 , wherein the parent strain of  N. caninum is NC- 1 which is present in MARC145 monkey kidney cells having ATCC accession No. CRL12231.  
   
   
       5 . (canceled)  
   
   
       6 . A vaccine to protect a mammal against neosporosis, comprising an immunologically effective amount of live cells of a strain derived from a pathogenic parent strain of a species of  Neospora,  which cells exhibit attenuated pathogenicity compared to those of the parent strain but which are capable of triggering an immune response that protects the mammal against neosporosis when administered as a live vaccine, and a veterinarily acceptable carrier.  
   
   
       7 . (canceled)  
   
   
       8 . The vaccine of  claim 6 , wherein the species of the parent strain is  N. caninum.    
   
   
       9 . The vaccine of  claim 8 , wherein the parent strain of  N. caninum  is NC-1 which is present in MARC145 monkey kidney cells having ATCC accession No. CRL12231.  
   
   
       10 . (canceled)  
   
   
       11 . The vaccine of  claim 6 , further comprising an adjuvant.  
   
   
       12 . The vaccine of  claim 11 , wherein the adjuvant is an oil-in-water emulsion.  
   
   
       13 . A method for preparing a culture of attenuated cells of a species of  Neospora  for use in a vaccine that protects a mammal against neosporosis, comprising modifying cells from a pathogenic parent strain of a species of  Neospora;  selecting and clonally propagating one or more modified cells that exhibit attenuated pathogenicity compared to cells of the parent strain; and selecting and clonally propagating one or more attenuated cells which are capable of triggering an immune response that protects the mammal against neosporosis when administered in a live vaccine.  
   
   
       14 . (canceled)  
   
   
       15 . The method of  claim 13 , wherein the species of the parent strain is  N. caninum.    
   
   
       16 . The method of  claim 15 , wherein the parent strain of  N. caninum  is NC-1 which is present in MARC145 monkey kidney cells having ATCC accession No. CRL-12231.  
   
   
       17 . A method for preparing a vaccine to protect a mammal against neosporosis, comprising modifying cells from a pathogenic parent strain of a species of  Neospora;  selecting and clonally propagating those modified cells that exhibit attenuated pathogenicity compared to cells of the parent strain but which are capable of triggering an immune response in the mammal that protects against neosporosis when administered in a live vaccine; and combining an immunologically effective amount of the attenuated cells with a veterinarily acceptable carrier in a form suitable for administration as a live vaccine to the mammal.  
   
   
       18 . (canceled)  
   
   
       19 . The method of  claim 17 , wherein the species of the parent strain is  N. caninum.    
   
   
       20 . The method of  claim 19 , wherein the parent strain of  N. caninum  is NC-1 which is present in MARC 145 monkey kidney cells having ATCC accession No. CRL-12231.  
   
   
       21 . The method of  claim 20 , wherein the strain of attenuated cells is NCTS-8 which is present in MARC145 monkey kidney cells having ATCC accession No. CRL-12230.  
   
   
       22 . The method of  claim 17 , further comprising adding an adjuvant to the vaccine.  
   
   
       23 . The method of  claim 22 , wherein the adjuvant is an oil-in-water emulsion.  
   
   
       24 . A method of vaccinating a mammal against neosporosis, comprising administering to the mammal an immunologically effective amount of a vaccine comprising live cells of a strain derived from a pathogenic parent strain of a species of  Neospora,  which cells exhibit attenuated pathogenicity compared to those of the parent strain but which are capable of triggering an immune response that protects the mammal against neosporosis when administered as a live vaccine, and a veterinarily acceptable carrier.  
   
   
       25 . (canceled)  
   
   
       26 . The method of  claim 24 , wherein the species of the parent strain is  N. caninum.    
   
   
       27 . The method of  claim 26 , wherein the parent strain of  N. caninum  is NC-1 which is present in MARC145 monkey kidney cells having ATCC accession No. CRL-12231.  
   
   
       28 . The method of  claim 27 , wherein the strain of attenuated cells is NCTS-8 which is present in MARC145 monkey kidney cells having ATCC accession No. CRL-12230.  
   
   
       29 . The method of  claim 24 , wherein the vaccine further comprises an adjuvant.  
   
   
       30 . The method of  claim 29 , wherein the adjuvant is an oil-in-water emulsion.  
   
   
       31 . The method of  claim 24 , wherein the mammal is selected from the group consisting of dogs, cows, goats, sheep and horses.  
   
   
       32 . A combination vaccine, comprising an immunologically effective amount of live cells of a strain derived from a pathogenic parent strain of a species of  Neospora,  which cells exhibit attenuated pathogenicity compared to those of the parent strain but which are capable of triggering an immune response that protects the mammal against neosporosis when administered as a live vaccine; one or more antigens that trigger an immune response that protects the mammal against a disease or a pathological condition; and a veterinarily acceptable carrier.

Join the waitlist — get patent alerts

Track US2006073157A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.